Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Sponsor trial record
Sponsor · clinical trials

Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our France register with Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts as lead sponsor. Synced 22 Nov 2026
7Current trials
6Recruiting now
0Drugs in these trials
1Trial register
At a glance

Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts is the lead sponsor of 7 current clinical trials in our France register. 6 are recruiting patients now. The most common phase is Not applicable. The most-studied condition is Glaucoma Associated With Other Ocular Disorders.

ClinicalTrials.gov trials by status

  • Recruiting686%
  • Not yet open114%

Trials by phase

  • Not applicable457%
  • Observational343%
01

Clinical trials sponsored by Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts

7 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
oCular Examination at Cell RESolution With Optical TransmissionTomography
NCT06976034 · ClinicalTrials.gov ↗ · Glaucoma Associated With Other Ocular Disorders
Not applicable Recruiting 2024-11 France
Natural History of Photoreceptor Degeneration in USH1B: Clinical Parameters and Validation of Functional Vision Tests in MYO7A
NCT07278843 · ClinicalTrials.gov ↗ · Usher Syndrome
Observational Recruiting 2025-10 France
Describe the Progression of Inflammatory Orbitopathy and the Biological Progression of Patients Receiving Second-line Treatment
NCT07117981 · ClinicalTrials.gov ↗ · Basedow Disease
Observational Recruiting 2024-11 France
Natural History Study of Usher Syndrome ( Light4Deaf )
NCT04665726 · ClinicalTrials.gov ↗ · Usher Syndromes
Observational Recruiting 2017-06 France
Implementation and Evaluation of a Post-Diagnostic Announcement Protocol at the CRMR RefeRet, Quinze-Vingts Hospital
NCT07292987 · ClinicalTrials.gov ↗ · Retinitis Pigmentosa (RP)
Not applicable Recruiting 2025-12 France
High Resolution, High-speed Multimodal Ophthalmic Imaging
NCT04129021 · ClinicalTrials.gov ↗ · Retinitis Pigmentosa, Maculopathy, Age Related, Macular Dystrophy
Not applicable Recruiting 2019-07 France
Feasibility and Tolerability Study of Smart Contact Lens With Healthy Subjects and Patients With Stargardt's Disease
NCT06989658 · ClinicalTrials.gov ↗ · Stargardt Disease
Not applicable Not yet open 2025-10 France

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Conditions in Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts trials

10 conditions
Glaucoma Associated With Other Ocular Disorders1Usher Syndrome1Stargardt Disease1Basedow Disease1Usher Syndromes1Retinitis Pigmentosa (RP)1Retinitis Pigmentosa1Maculopathy, Age Related1Macular Dystrophy1Macular Edema1
03

By trial register

RegisterTrialsRecruiting
Clinical trials in France76

A trial with sites in more than one country appears in each of those registers.

04

Questions about Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts trials

How many clinical trials does Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts sponsor?

Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts is the lead sponsor of 7 current trials on ClinicalTrials.gov in our France register, as of the registry sync on 22 November 2026. Completed and withdrawn studies are not counted.

Are Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts trials recruiting?

Yes. 6 of its 7 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 22 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.